PE20221026A1 - Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria - Google Patents

Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria

Info

Publication number
PE20221026A1
PE20221026A1 PE2022000770A PE2022000770A PE20221026A1 PE 20221026 A1 PE20221026 A1 PE 20221026A1 PE 2022000770 A PE2022000770 A PE 2022000770A PE 2022000770 A PE2022000770 A PE 2022000770A PE 20221026 A1 PE20221026 A1 PE 20221026A1
Authority
PE
Peru
Prior art keywords
compounds
treatment
naftyridin
autoimmune disease
6alkyl
Prior art date
Application number
PE2022000770A
Other languages
English (en)
Inventor
Hong Shen
Xiaoqing Wang
Hongtao Xu
Zhisen Zhang
Wei Zhu
Ge Zou
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20221026A1 publication Critical patent/PE20221026A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invencion se refiere a compuestos derivados de 1,8-naftiridin-2-ona de formula (I) y (Ia) o una sal farmaceutica de este, donde: R1 y R2 son alquilo C1-6; R3 es (alcoxiC1-6alquilC1-6)piperazinilo, (alquilC1-6)2aminoalcoxiC1-6, entre otros. Tambien se refiere a un proceso de preparacion y a una composicion farmaceutica. Dichos compuestos son antagonistas de los receptores tipo Toll (TLR): TLR7, TLR8 o TLR9, siendo utiles en el tratamiento de lupus eritematoso sistemico o nefritis lupica.
PE2022000770A 2019-11-26 2020-11-24 Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria PE20221026A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019120996 2019-11-26
PCT/EP2020/083113 WO2021105072A1 (en) 2019-11-26 2020-11-24 1,8-naphthyridin-2-one compounds for the treatment of autoimmune disease

Publications (1)

Publication Number Publication Date
PE20221026A1 true PE20221026A1 (es) 2022-06-16

Family

ID=73598065

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022000770A PE20221026A1 (es) 2019-11-26 2020-11-24 Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria

Country Status (16)

Country Link
US (1) US20230041743A1 (es)
EP (1) EP4065586A1 (es)
JP (1) JP2023503165A (es)
KR (1) KR20220106126A (es)
CN (1) CN114728987A (es)
AR (1) AR120540A1 (es)
AU (1) AU2020393367A1 (es)
BR (1) BR112022009856A2 (es)
CA (1) CA3156457A1 (es)
CO (1) CO2022006942A2 (es)
CR (1) CR20220231A (es)
IL (1) IL291640A (es)
MX (1) MX2022005912A (es)
PE (1) PE20221026A1 (es)
TW (1) TW202134238A (es)
WO (1) WO2021105072A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4273773A (en) * 1979-09-24 1981-06-16 American Home Products Corporation Antihypertensive tricyclic isoindole derivatives
WO2014123167A1 (ja) * 2013-02-08 2014-08-14 日産化学工業株式会社 ３環性ピロロピリジン化合物及びｊａｋ阻害剤
EP3889145B1 (en) * 2015-12-17 2024-02-21 Merck Patent GmbH 8-cyano-5-piperidino-quinolines as tlr7/8 antagonists and their uses for treating immune disorders
JP7344125B2 (ja) * 2017-03-30 2023-09-13 エフ． ホフマン－ラ ロシュ アーゲー 細菌感染の治療及び予防のための新規ピリド［２，３－ｂ］インドール化合物
EP3612030A4 (en) * 2017-04-21 2021-04-28 Ikena Oncology, Inc. AHR INDOLE INHIBITORS AND THEIR USES

Also Published As

Publication number Publication date
TW202134238A (zh) 2021-09-16
JP2023503165A (ja) 2023-01-26
CN114728987A (zh) 2022-07-08
WO2021105072A1 (en) 2021-06-03
US20230041743A1 (en) 2023-02-09
IL291640A (en) 2022-05-01
AR120540A1 (es) 2022-02-23
BR112022009856A2 (pt) 2022-08-02
CR20220231A (es) 2022-06-27
CA3156457A1 (en) 2021-06-03
CO2022006942A2 (es) 2022-06-10
MX2022005912A (es) 2022-06-24
AU2020393367A1 (en) 2022-04-14
KR20220106126A (ko) 2022-07-28
EP4065586A1 (en) 2022-10-05

Similar Documents

Publication Publication Date Title
UY37007A (es) Compuestos derivados de purinas, estimuladores de genes de interferón
DOP2021000019A (es) Inhibidores de inflamasoma nlrp3
PE20210131A1 (es) COMPUESTOS TETRAHIDRO-1H-PIRAZINO[2,1-a]ISOINDOLILQUINOLINA PARA EL TRATAMIENTO DE ENFERMEDADES AUTOINMUNES
PE20190705A1 (es) COMPUESTOS DE BENZO[b] TIOFENO COMO AGONISTAS DE STING
PE20211203A1 (es) Compuestos para el tratamiento de trastornos dependientes de cinasas
AR112414A1 (es) Agonistas del receptor tipo toll 7 (tlr7) que tienen una porción benzotriazol, conjugados de estos y métodos y usos de estos
CY1124239T1 (el) Ενωσεις αμινο-τριαζολοπυριδινης και χρηση αυτων στην αγωγη του καρκινου
MX2019000694A (es) Compuestos indol sustituidos con dimetoxifenilo como inhibidores de receptores tipo toll 7, 8 o 9 (tlr7, tlr8 o tlr9).
PE20181298A1 (es) Inhibidores de bromodominio bivalentes y usos de los mismos
CY1124113T1 (el) Συνθεσεις και μεθοδοι για την θεραπευτικη αντιμετωπιση διαταραχων κνς
PE20200701A1 (es) Agonistas del receptor tipo toll 7 (tlr7) que tienen una porcion heterobiarilo, conjugados de estos y metodos y usos de estos
MD3601283T2 (ro) Compus inhibitor JAK pe bază de imidazo-piperidină fuzionată
CU20170162A7 (es) Derivados de fenil-tieno(2,3-d)pirimidina-hidroxiácido útiles en el tratamiento del cáncer y enfermedades autoinmunes, método de preparación de los mismos y composiciones farmacéuticas que los contienen
PE20151651A1 (es) Derivado de tetrahidroimidazol[1,5-d][1,4]oxazepina
PE20142400A1 (es) Compuestos novedosos
CY1115175T1 (el) Ενωσεις 9-υποκατεστημενης-8-οξο-αδενινης ως ρυθμιστες υποδοχεων τυπου toll (tlr7)
CL2020001343A1 (es) Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson.
PE20190476A1 (es) Compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infeccion virica
AR082946A1 (es) Imidazopiridazinas sustituidas
AR083849A1 (es) Antagonistas de mdm2 de espiro-oxindol
ECSP10010513A (es) Compuestos y composiciones como moduladores de la actividad de tlr
PE20190504A1 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
CY1112601T1 (el) Υποκατεστημενα παραγωγα 1-πιπεριδιν-4-υλ-4-πυρρολιδιν-3-υλ-πιπεραζινης και χρηση αυτων ως ανταγωνιστων νευροκινινης
PE20090890A1 (es) Compuestos derivados de 1-(2,3-dihidrobenzo[1,4]dioxin-2-ilmetil)azaciclos como antagonistas del suptipo adrenoreceptor alfa2c
AR116116A1 (es) Proceso para elaborar inhibidores de jak e intermediarios de los mismos